ZELNORM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zelnorm, and what generic alternatives are available?
Zelnorm is a drug marketed by Alfasigma and is included in one NDA.
The generic ingredient in ZELNORM is tegaserod maleate. Additional details are available on the tegaserod maleate profile page.
Summary for ZELNORM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Patent Applications: | 535 |
| Drug Prices: | Drug price information for ZELNORM |
| What excipients (inactive ingredients) are in ZELNORM? | ZELNORM excipients list |
| DailyMed Link: | ZELNORM at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ZELNORM
US Patents and Regulatory Information for ZELNORM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alfasigma | ZELNORM | tegaserod maleate | TABLET;ORAL | 021200-001 | Jul 24, 2002 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Alfasigma | ZELNORM | tegaserod maleate | TABLET;ORAL | 021200-002 | Jul 24, 2002 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZELNORM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alfasigma | ZELNORM | tegaserod maleate | TABLET;ORAL | 021200-001 | Jul 24, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
| Alfasigma | ZELNORM | tegaserod maleate | TABLET;ORAL | 021200-002 | Jul 24, 2002 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZELNORM
See the table below for patents covering ZELNORM around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Czech Republic | 284339 | Aminoguanidiny, způsob jejich výroby a farmaceutické kompozice tyto guanidiny obsahující (INDOLE COMPOUND, PROCESS OF ITS PREPARATION, THE INDOLE COMPOUND AS A MEDICAMENT AND PHARMACEUTICAL COMPOSITION ION WHICH THE INDOLE COMPOUND IS COMPRISED) | ⤷ Try a Trial |
| Russian Federation | 2095347 | AMINOGUAMIDINES, METHOD OF PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITION BASED THEREON | ⤷ Try a Trial |
| Slovakia | 279214 | ⤷ Try a Trial | |
| Hungary | T64023 | ⤷ Try a Trial | |
| Austria | 170838 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ZELNORM
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0505322 | C00505322/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: TEGASEROD; REGISTRATION NO/DATE:IKS 55689 20011030 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
